Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 13:30 save search
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 13:30) - biospace.com/
MTEM | $1.455 -2.02% -2.06% 13K
|
Health Technology
|
| O: 9.73%
H: 0.49%
C: -8.87%
mt-6402 association tumors cancer research for meeting molecular study
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Published: 2024-03-20 (Crawled : 13:30) - globenewswire.com
IMMX | $2.21 0.0% 64K
|
|
| O: -2.9%
H: 10.07%
C: 2.24%
nxc-201 cancer biopharma trial
Bayer and Thermo Fisher Scientific collaborate to increase patient access to precision cancer medicines
Published: 2024-03-20 (Crawled : 13:30) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.29%
H: 0.1%
C: -0.17%
precision cancer
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
ILMN | $117.43 0.63% 0.63% 1.4M
|
Health Technology
|
| O: 0.51%
H: 2.49%
C: 1.37%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.45%
H: 0.55%
C: -0.24%
lung test cancer risk study
QT Imaging’s Breast Acoustic CT™ Scanner Used in Study for Early Identification of Response of Breast Cancer Patients to Neoadjuvant Chemotherapy
Published: 2024-03-14 (Crawled : 13:30) - biospace.com/
GIA | $1.08 237.96% 1.4K
|
| Email alert
Add to watchlist
breast cancer response study
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - globenewswire.com
ELTX | $8.465 2.86% 2.78% 28K
|
|
| O: -0.73%
H: 2.95%
C: 1.72%
association cancer research meeting therapeutics
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 0.82%
H: 0.0%
C: 0.0%
cancer market
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
LIXT | $3.351 4.68% 11K
|
Health Technology
|
| O: 3.17%
H: 23.6%
C: 17.11%
lb-100 conference pre-clinical cancer research
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Published: 2024-02-27 (Crawled : 13:30) - globenewswire.com
IMNN | $1.16 3.11% 3.02% 95K
|
Manufacturing
|
| O: 4.08%
H: 13.39%
C: 11.81%
imnn-001 cancer trial advanced
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
KA A | $0.5196 6.89% 6.45% 480K
|
Manufacturing
|
| O: 1.15%
H: 5.31%
C: -0.76%
kva1212 antibody symposium cancer blood preclinical leukemia
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
lung opdivo cancer cell
Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
EXAI | $4.24 -2.75% -2.83% 370K
|
|
| O: 1.02%
H: 0.0%
C: -1.68%
precision cancer study platform
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
Published: 2024-02-06 (Crawled : 13:30) - globenewswire.com
BCTX | $2.19 -5.6% -5.94% 140K
|
Professional, Scientific, and T...
|
| O: 9.41%
H: 1.16%
C: -3.72%
candidate cancer
New Study Validates Signatera™ in Endometrial Cancer
Published: 2024-02-05 (Crawled : 13:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: -0.89%
H: 2.74%
C: 2.52%
cancer study
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
CANF | $1.99 1.02% -0.5% 7.8K
|
Health Technology
|
| O: 5.24%
H: 2.71%
C: -4.75%
cancer pancreatic deal
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
Published: 2024-01-30 (Crawled : 13:30) - biospace.com/
NTRA S | $85.275 -2.3% -2.35% 2.5M
|
Health Services
|
| O: -1.07%
H: 1.73%
C: 0.46%
lung cancer publication risk
TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
RNAZ | $0.49 -2.39% -2.45% 110K
|
Professional, Scientific, and T...
|
| O: 14.42%
H: 1.21%
C: -10.29%
cancer collaboration therapeutics
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Published: 2024-01-25 (Crawled : 13:30) - globenewswire.com
PCSA | $1.58 1.28% 1.27% 19K
|
Producer Manufacturing
|
| O: 78.05%
H: 61.92%
C: 39.73%
cancer pharmaceuticals advanced
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
Published: 2024-01-24 (Crawled : 13:30) - globenewswire.com
EVAX | $4.2 -0.47% -0.48% 31K
|
Manufacturing
|
| O: 86.97%
H: 45.87%
C: 14.15%
cancer
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Published: 2024-01-23 (Crawled : 13:30) - biospace.com/
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 0.0%
H: 3.09%
C: 1.03%
patent vaccine cancer technology
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.